Back to dashboard
All PlansCoverageMedium impact

Evaluation of Biomarkers for Alzheimer Disease

Blue Cross & Blue Shield of Mississippi·MS · Neurology, Family Medicine, Internal Medicine +1 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This is a new medical policy (A.2.04.14) establishing coverage guidelines for Alzheimer's disease biomarker testing, including CSF, blood, and urine tests for amyloid beta peptide 1-42, tau proteins, and neurogranin. The policy provides comprehensive background on Alzheimer's disease pathophysiology and biomarker evaluation but does not specify coverage determinations or billing requirements.

Action Required

Action needed
Review new policy A.2.04.14 for Alzheimer's disease biomarker evaluation to understand coverage framework. Monitor for upcoming coverage determination updates that will specify which biomarker tests are covered and any prior authorization requirements. Ensure billing team is familiar with Alzheimer's biomarker testing procedures for future billing scenarios.

Related policy hubs